Results 21 to 30 of about 17,756 (247)

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia [PDF]

Nature Communications, 2021
Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell persistence.
Nadia El Khawanky, Amy Hughes, Wenbo Yu, R. Myburgh, Tony Matschulla, S. Taromi, K. Aumann, J. Clarson, J. M. Vinnakota, K. Shoumariyeh, C. Miething, A. Lopez, Michael P. Brown, J. Duyster, L. Hein, M. Manz, T. Hughes, D. White, A. Yong, R. Zeiser   +19 more
semanticscholar   +2 more sources

Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

Drug Delivery, 2017
Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand.
Haibin Wu, Meng Wang, Bo Dai, Yanmin Zhang, Ying Yang, Qiao Li, Mingyue Duan, Xi Zhang, Xiaomei Wang, Anmao Li, Liyu Zhang   +10 more
doaj   +2 more sources

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Haematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej N. Konoplev, Haitham Khogeer, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler-McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias J. Jabbour, Joseph D. Khoury   +14 more
doaj   +4 more sources

Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients

Advances in Hematology, 2020
This study aimed to determine the clinical impact of CD25+/CD123+ coexpression in adult B-cell acute lymphoblastic leukemia (B-ALL) cases. One hundred and twenty newly diagnosed B-ALL patients (≤60 years old) were included in this study.
Salah Aref, Mohamed El Agdar, Nada Khaled, Lamyaa Ibrahim, Mohamed S. El-Ghonemy   +4 more
doaj   +2 more sources

Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients

Journal of Applied Hematology, 2014
Background: The genomic alterations in acute myeloid leukemia (AML) affect the function of signaling molecules, transcription factors, and growth factor receptors besides they influence the response to treatment. Interleukin-3 receptor alpha chain (CD123)
Inas Asfour, Soha Yoyssef, Maryse Ayoub, Nevine Moustafa, Hani Ayash, Tussneem Elhassan, Ghada M ElGohary   +6 more
doaj   +2 more sources

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy

Drug Delivery, 2021
CD123 targeting molecules have been widely applied in acute myelocytic leukemia (AML) therapeutics. Although antibodies have been more widely used as targeting molecules, aptamer have unique advantages for CD123 targeting therapy.
Haibin Wu, Liyu Zhang, Zeen Zhu, Chenxi Ding, Shengquan Chen, Ruiping Liu, Huafeng Fan, Yang Chen, Hui Li   +8 more
doaj   +2 more sources

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors [PDF]

Haematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Amber Gordon, Donna Bucci, David M. Lucas, Alice Mims, Christopher Brooks, Adrienne Dorrance, Alison Walker, William Blum, John C. Byrd, Gerard Lozanski, Sumithira Vasu, Natarajan Muthusamy   +18 more
doaj   +2 more sources

The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes

Haematologica, 2004
BACKGROUND AND OBJECTIVES: CD123 is an antibody that identifies the a chain of the human interleukin-3 receptor and is expressed in a variety of normal hematopoietic cells, acute leukemia and hairy cell leukemia (HCL).
I Del Giudice, E Matutes, R Morilla, A Morilla, K Owusu-Ankomah, F Rafiq, R A'Hern, J Delgado, MB Bazerbashi, D Catovsky   +9 more
doaj   +1 more source

Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts [PDF]

Cell Journal, 2021
Objective: The clinical studies of acute myeloid leukaemia (AML) revealed that antigen escaping variants cause cancer recurrence even after treatment with chimeric antigen receptor (CAR)-T cells that target a single tumour antigen.
Ali Ghamari, Parviz Pakzad, Ahmad Majd, Marzieh Ebrahimi, Amir Ali Hamidieh   +4 more
doaj   +1 more source

Analyses of the clinical and immunological characteristics of patients with lupus erythematosus

Indian Journal of Dermatology, 2022
Background: Lupus erythematosus (LE) is a broad-spectrum, heterogeneous disease. At one end of the spectrum is the cutaneous LE (CLE) without systemic involvement, and at the other end is the systemic LE (SLE) with multisystem involvement.
Min Deng, Ruifang Wu, Xingyu Zhou, Yuwen Su, Yaping Li   +4 more
doaj   +1 more source